Pfizer: Who We Are
•
5 likes•2,678 views
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
Report
Share
Report
Share
Recommended
Pfizer
Pfizer is a large pharmaceutical company founded in 1849 and headquartered in New York. It has annual sales of $44.4 billion and focuses on areas like cardiovascular, infectious diseases, and oncology. While Pfizer has significant market share and resources, it also faces threats such as expiring patents, increased competition from generics, and a reliance on blockbuster drugs.
Pfizer Inc
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
mba 599- pfizer
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
Pfizer company analysis
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
Pfizer-Strategic Management Case
Pfizer is a large pharmaceutical company founded in 1849. In 2014, Pfizer's revenue was $53.8 billion with net income of $22 billion. Pfizer's top selling drugs include Lipitor, Lyrica, and Viagra. The company is evaluating strategic options to maintain its leadership position, including horizontal integration through an acquisition of AstraZeneca. In May 2014, Pfizer offered $117 billion for AstraZeneca, but the offer was rejected. Pfizer will likely need to make another major acquisition in the next 4-5 years to continue growing and remain the largest pharmaceutical company.
Strategic Management presentation for a Pharmaceutical Industry
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
About Pfizer Company
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
BUSINESS STARATEGY AND POLICY PROJECT
Pfizer Inc. is the world's largest pharmaceutical company with global operations in over 79 locations. The company applies science and resources to develop therapies that improve lives. Pfizer divides its business into innovative pharmaceuticals, vaccines and consumer healthcare. Key products include Prevnar/Prevenar 13, Lyrica, and Viagra. While facing competition from generic drugs and facing high barriers to entry, Pfizer maintains a leading market position through a diverse portfolio and strong brand recognition.
Recommended
Pfizer
Pfizer is a large pharmaceutical company founded in 1849 and headquartered in New York. It has annual sales of $44.4 billion and focuses on areas like cardiovascular, infectious diseases, and oncology. While Pfizer has significant market share and resources, it also faces threats such as expiring patents, increased competition from generics, and a reliance on blockbuster drugs.
Pfizer Inc
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
mba 599- pfizer
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
Pfizer company analysis
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
Pfizer-Strategic Management Case
Pfizer is a large pharmaceutical company founded in 1849. In 2014, Pfizer's revenue was $53.8 billion with net income of $22 billion. Pfizer's top selling drugs include Lipitor, Lyrica, and Viagra. The company is evaluating strategic options to maintain its leadership position, including horizontal integration through an acquisition of AstraZeneca. In May 2014, Pfizer offered $117 billion for AstraZeneca, but the offer was rejected. Pfizer will likely need to make another major acquisition in the next 4-5 years to continue growing and remain the largest pharmaceutical company.
Strategic Management presentation for a Pharmaceutical Industry
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
About Pfizer Company
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
BUSINESS STARATEGY AND POLICY PROJECT
Pfizer Inc. is the world's largest pharmaceutical company with global operations in over 79 locations. The company applies science and resources to develop therapies that improve lives. Pfizer divides its business into innovative pharmaceuticals, vaccines and consumer healthcare. Key products include Prevnar/Prevenar 13, Lyrica, and Viagra. While facing competition from generic drugs and facing high barriers to entry, Pfizer maintains a leading market position through a diverse portfolio and strong brand recognition.
Pfizer Inc
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of Pfizer's financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Pfizer strategy for internationalization
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
Pfizer case study
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
The document is a letter of transmittal from a team of students to their professors submitting a report analyzing the global pharmaceutical companies Merck & Co. and Sanofi. The team's analysis identified three key success factors for companies in the industry and concluded that based on these factors, Sanofi is currently in a better position than Merck & Co. to succeed. The letter requests feedback from the professors and offers to further discuss the report and its analyses and recommendations.
Pfizer Strategic Analysis
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
Pfizer business strategy
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
Pfizer to Acquire Wyeth
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
Novartis ppt
With the quantity of pharmaceutical industry expanding each day,competition inside the business is wild.Novartis is pharmaceutical industry.. This year, Novartis experienced success with oncology, immunology and dermatology, eye care and biosimilars.
Business Report on Pfizer
This document provides a business report on Pfizer Inc. prepared by Aileen Marshall. It includes an executive summary analyzing Pfizer's position in the pharmaceutical market. It then gives a company snapshot of Pfizer, including key facts, products, acquisitions and financial performance. Finally, it begins an analysis of Pfizer's current position using a PEST analysis and SWOT analysis to examine political, economic, social, technical, strengths, weaknesses, opportunities and threats facing the company.
Competitive Analysis of Abbott Laboratories
Abbott Laboratories (Pakistan) is a pharmaceutical company founded in 1888 that has been operating in Pakistan since 1948. It has over 1,500 employees and manufacturing facilities in Karachi. The company produces pharmaceuticals, nutritional products, diagnostics, and medical devices. Abbott's main competitors in Pakistan include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, and Pfizer. An analysis of Abbott's strengths, weaknesses, opportunities, and threats was conducted, as well as financial analysis showing steady growth from 2012-2017. Recommendations included focusing on products with fewer side effects, reducing employee turnover, engaging with the government, and adopting new technologies.
Pfizer project management
Pfizer exists to develop new, safe medicines to treat serious diseases and make them available to those in need. They strive to positively impact global health through philanthropy focused on increasing access to medicines, healthcare services, and capacity building. Currently, Pfizer prioritizes research in immunology, oncology, cardiovascular, neuroscience, and vaccines through small molecules, biologics and vaccines. They have expanded research and manufacturing facilities globally to grow their reputation and market value.
Value Chain Analysis of Glaxo Smith Kline
GlaxoSmithKline is one of the world's leading research-based pharmaceutical companies committed to improving human life. It has a fast growth rate and strong presence in Bangladesh. GSK's vision is to become the undisputed industry leader through size and using size to achieve their mission. Their mission is to improve quality of life by enabling people to do more, feel better and live longer. GSK has a strong competitive advantage through their focus on R&D and exploring new markets. Their value chain involves manufacturing, marketing, and services alongside firm infrastructure, human resource management, and research development activities such as tackling antibiotic resistance.
Strategic Analysis - Sanofi Aventis
Strategic Analysis of Sanofi Aventis and key recomendations.
Team work for Strategic Management course, SMIB 2011 (Essec Business School)
Pharmaceuticals - Industry Value Chain
This document outlines the key processes involved in drug development and distribution including drug formulation, ingredient sourcing and traceability, quality management systems, warehouse management, order processing, regulatory compliance, and customer relationship management. It discusses stages from research and development through manufacturing, warehousing, sales, and quality control to ensure safety and meet regulatory requirements.
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical company headquartered in London, UK. It is the 3rd largest pharmaceutical company by revenue and has leading market share in anti-infectives, central nervous system, respiratory, and gastrointestinal drugs. GSK spends over $450,000 per hour on research and development and has acquired several companies in recent years to expand its product portfolio. The company's business model focuses on several therapeutic areas with respiratory, central nervous system, and vaccines being the largest segments by revenue.
Muhammad ehsan 19576 report (3)
Getz Pharmaceutical is Pakistan's largest branded generic pharmaceutical company. It has a diverse product portfolio and fast-growing sales force. The company sees opportunities in expanding into untapped territories and growing disease categories like diabetes. However, it faces threats from changing regulations, cost pressures, and new entrants. Getz aims to address issues and seize opportunities by strengthening its sales training, considering technology to aid its workforce, and exploring partnerships or acquisitions.
Pfizer & Pharmacia Merger
Pfizer acquired Pharmacia in 2003 in the largest pharmaceutical merger in history, valued at $60 billion. The merger strengthened Pfizer's portfolio in areas like oncology and endocrinology. It combined Pfizer's leadership in pharmaceutical revenues with Pharmacia's research in key therapeutic areas. However, the merger also led to facility closures and job cuts as the companies integrated operations. Overall, the merger positioned Pfizer as a global pharmaceutical leader through enhanced R&D capabilities and a broader product portfolio.
Pfizer-a pharmaceutical company
Pfizer is a global pharmaceutical company founded in 1849 and headquartered in New York. It produces medicines and vaccines. The document discusses Pfizer's global inventory management strategy, including inventory control techniques like reorder levels and safety stock levels. It also covers Pfizer's focus on efficiency, resilience, agility, quality control, and supply chain best practices and challenges. The presentation was submitted by Milind and team to Prof. Jaison Mathews.
Rx to OTC switch by Dr. Zubair Ali
This document discusses factors related to switching medications from prescription to over-the-counter status. It begins by defining Rx-to-OTC switching as transferring FDA-approved prescription medications to non-prescription, over-the-counter status. The document then covers stakeholders impacted by switching, the switching process and principles, factors contributing to successful switches, considerations for switches, and strategies for building brand equity during and after a switch from prescription to over-the-counter status.
Mergers and Acquisitions in Pharmaceutical Industry
Mergers and acquisitions have impacted the pharmaceutical industry in several ways. They allow companies to expand their product portfolios and markets through acquiring complementary assets. However, they can also lead to job losses as companies consolidate. Major deals like Pfizer-Wyeth and Ranbaxy-Daichi Sankyo helped the companies strengthen their product pipelines but some deals negatively impacted R&D productivity and employee satisfaction in the long run. Overall, M&As in pharma aim to create shareholder value but often fail to achieve synergies.
Pfizer Social Media Analysis Q4 2015
Have a look at the social media metrics behind Pfizer's incredible social media efforts. See the strategies that drove audience engagement and the brand content that outperformed all others.
More Related Content
What's hot
Pfizer Inc
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of Pfizer's financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Pfizer strategy for internationalization
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
Pfizer case study
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
The document is a letter of transmittal from a team of students to their professors submitting a report analyzing the global pharmaceutical companies Merck & Co. and Sanofi. The team's analysis identified three key success factors for companies in the industry and concluded that based on these factors, Sanofi is currently in a better position than Merck & Co. to succeed. The letter requests feedback from the professors and offers to further discuss the report and its analyses and recommendations.
Pfizer Strategic Analysis
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
Pfizer business strategy
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
Pfizer to Acquire Wyeth
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
Novartis ppt
With the quantity of pharmaceutical industry expanding each day,competition inside the business is wild.Novartis is pharmaceutical industry.. This year, Novartis experienced success with oncology, immunology and dermatology, eye care and biosimilars.
Business Report on Pfizer
This document provides a business report on Pfizer Inc. prepared by Aileen Marshall. It includes an executive summary analyzing Pfizer's position in the pharmaceutical market. It then gives a company snapshot of Pfizer, including key facts, products, acquisitions and financial performance. Finally, it begins an analysis of Pfizer's current position using a PEST analysis and SWOT analysis to examine political, economic, social, technical, strengths, weaknesses, opportunities and threats facing the company.
Competitive Analysis of Abbott Laboratories
Abbott Laboratories (Pakistan) is a pharmaceutical company founded in 1888 that has been operating in Pakistan since 1948. It has over 1,500 employees and manufacturing facilities in Karachi. The company produces pharmaceuticals, nutritional products, diagnostics, and medical devices. Abbott's main competitors in Pakistan include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, and Pfizer. An analysis of Abbott's strengths, weaknesses, opportunities, and threats was conducted, as well as financial analysis showing steady growth from 2012-2017. Recommendations included focusing on products with fewer side effects, reducing employee turnover, engaging with the government, and adopting new technologies.
Pfizer project management
Pfizer exists to develop new, safe medicines to treat serious diseases and make them available to those in need. They strive to positively impact global health through philanthropy focused on increasing access to medicines, healthcare services, and capacity building. Currently, Pfizer prioritizes research in immunology, oncology, cardiovascular, neuroscience, and vaccines through small molecules, biologics and vaccines. They have expanded research and manufacturing facilities globally to grow their reputation and market value.
Value Chain Analysis of Glaxo Smith Kline
GlaxoSmithKline is one of the world's leading research-based pharmaceutical companies committed to improving human life. It has a fast growth rate and strong presence in Bangladesh. GSK's vision is to become the undisputed industry leader through size and using size to achieve their mission. Their mission is to improve quality of life by enabling people to do more, feel better and live longer. GSK has a strong competitive advantage through their focus on R&D and exploring new markets. Their value chain involves manufacturing, marketing, and services alongside firm infrastructure, human resource management, and research development activities such as tackling antibiotic resistance.
Strategic Analysis - Sanofi Aventis
Strategic Analysis of Sanofi Aventis and key recomendations.
Team work for Strategic Management course, SMIB 2011 (Essec Business School)
Pharmaceuticals - Industry Value Chain
This document outlines the key processes involved in drug development and distribution including drug formulation, ingredient sourcing and traceability, quality management systems, warehouse management, order processing, regulatory compliance, and customer relationship management. It discusses stages from research and development through manufacturing, warehousing, sales, and quality control to ensure safety and meet regulatory requirements.
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical company headquartered in London, UK. It is the 3rd largest pharmaceutical company by revenue and has leading market share in anti-infectives, central nervous system, respiratory, and gastrointestinal drugs. GSK spends over $450,000 per hour on research and development and has acquired several companies in recent years to expand its product portfolio. The company's business model focuses on several therapeutic areas with respiratory, central nervous system, and vaccines being the largest segments by revenue.
Muhammad ehsan 19576 report (3)
Getz Pharmaceutical is Pakistan's largest branded generic pharmaceutical company. It has a diverse product portfolio and fast-growing sales force. The company sees opportunities in expanding into untapped territories and growing disease categories like diabetes. However, it faces threats from changing regulations, cost pressures, and new entrants. Getz aims to address issues and seize opportunities by strengthening its sales training, considering technology to aid its workforce, and exploring partnerships or acquisitions.
Pfizer & Pharmacia Merger
Pfizer acquired Pharmacia in 2003 in the largest pharmaceutical merger in history, valued at $60 billion. The merger strengthened Pfizer's portfolio in areas like oncology and endocrinology. It combined Pfizer's leadership in pharmaceutical revenues with Pharmacia's research in key therapeutic areas. However, the merger also led to facility closures and job cuts as the companies integrated operations. Overall, the merger positioned Pfizer as a global pharmaceutical leader through enhanced R&D capabilities and a broader product portfolio.
Pfizer-a pharmaceutical company
Pfizer is a global pharmaceutical company founded in 1849 and headquartered in New York. It produces medicines and vaccines. The document discusses Pfizer's global inventory management strategy, including inventory control techniques like reorder levels and safety stock levels. It also covers Pfizer's focus on efficiency, resilience, agility, quality control, and supply chain best practices and challenges. The presentation was submitted by Milind and team to Prof. Jaison Mathews.
Rx to OTC switch by Dr. Zubair Ali
This document discusses factors related to switching medications from prescription to over-the-counter status. It begins by defining Rx-to-OTC switching as transferring FDA-approved prescription medications to non-prescription, over-the-counter status. The document then covers stakeholders impacted by switching, the switching process and principles, factors contributing to successful switches, considerations for switches, and strategies for building brand equity during and after a switch from prescription to over-the-counter status.
Mergers and Acquisitions in Pharmaceutical Industry
Mergers and acquisitions have impacted the pharmaceutical industry in several ways. They allow companies to expand their product portfolios and markets through acquiring complementary assets. However, they can also lead to job losses as companies consolidate. Major deals like Pfizer-Wyeth and Ranbaxy-Daichi Sankyo helped the companies strengthen their product pipelines but some deals negatively impacted R&D productivity and employee satisfaction in the long run. Overall, M&As in pharma aim to create shareholder value but often fail to achieve synergies.
What's hot (20)
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
Mergers and Acquisitions in Pharmaceutical Industry
Mergers and Acquisitions in Pharmaceutical Industry
Viewers also liked
Pfizer Social Media Analysis Q4 2015
Have a look at the social media metrics behind Pfizer's incredible social media efforts. See the strategies that drove audience engagement and the brand content that outperformed all others.
Pfizer at Citi Global Health Care Conference
The document is a presentation from Pfizer's CFO at a healthcare conference in May 2008. It summarizes Pfizer's strategies to: 1) maximize revenues from existing, new, and diverse product sources; 2) establish a lower, more flexible cost base; and 3) innovate its business model. The presentation provides details on optimizing Pfizer's patent-protected portfolio, capitalizing on established products, growing in emerging markets, proven cost management track record, and 2008 financial guidance.
Dr. Liam Tully, Director, Pfizer Global Development Process Centre
The document discusses how innovation in pharmaceutical manufacturing processes can improve competitiveness. It argues that the manufacturing process has the biggest impact on competitiveness through cost and new opportunities. However, many Irish pharmaceutical companies do not focus on innovating their manufacturing processes as part of their competitiveness strategies. The document outlines how implementing a formal innovation program and focusing on the manufacturing process can help drive significant cost savings and value, as shown through Pfizer's global process development center case study which delivered over $2 billion in value through process redesigns.
Presentation by Cliff Fullers
The document summarizes a New Zealand workshop discussing opportunities for linking business clusters in India and New Zealand. It outlines the agenda which includes introductions, examples of dairy and wool cluster interactions between the two countries, and a discussion on future potential cluster linkages. Examples provided include opportunities in the aviation, technology, building products, healthcare and other industries. The workshop aims to identify ways for large New Zealand clusters to partner with related small clusters in India to create international business opportunities.
Social Media 101
Wonder why social media is suddenly such a hot commodity? Wish you knew how the most popular platforms worked, and what kinds of communities they created? Curious about how you can use social media for business, or even in an Advanced Writing classroom? You're in the right place.
Presentation by Kay Choe
Cluster-based City Economic Development (CCED): Analytical Methodology Assessing Cluster Competitiveness
Capsugel core business ad
Capsugel, the global leader in capsule manufacturing, needed to entice their customers with a broad range of capabilities. By simplifying the message and adding a new tag line, I brought a sense of lightheartedness and unity to the ad.
Pfizer Case Study
Pfizer implemented green chemistry principles in one of its production lines to reduce waste and use safer chemicals. This included eliminating the use of solvents and reducing the number of production steps. Pfizer saw a 25% reduction in waste and expects similar reductions by applying these principles to other production lines. The document also includes a diagram explaining the waste stream from raw materials to final waste disposal.
Fill Finish Contract Manufacturer Quality Benchmarking (2016)
As pharmaceutical and biopharmaceutical companies increase their levels of external development and manufacturing, the need for unbiased information to support strategic business decisions continues to grow. In this report, ISR provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality across a series of 26 performance attributes specific to drug product manufacturing projects. In this Consumer Reports-style analysis, ISR presents data on 423 service encounters from 217 respondents who have been involved in outsourced fill finish projects in the past 18 months.
Xcelience Formulation Development
Partnering with a specialist like Xcelience for early phase small molecule development can accelerate timelines and reduce product risk.
Presentation done by Rajveer Singh
The document discusses clusters in India, including their size, geographical distribution, and major characteristics. It notes that there are over 1,200 clusters in India covering 321 products, which collectively account for approximately 30% of total manufacturing output. The largest clusters are located in the northern, western, and southern regions of India. Common characteristics of Indian clusters include historically evolving over time, flexibility to meet demand, focus on the domestic market, high levels of subcontracting, and defined boundaries. The document also provides examples of prominent Indian clusters and assesses their competitiveness using a diamond model analysis framework.
Indian nutra market
The Indian nutraceuticals market was estimated to be worth $2 billion in 2010 and is expected to reach $5 billion by 2015. Functional foods and beverages are predicted to experience stronger growth than dietary supplements. Diabetic functional foods and enhanced drinks and energy beverages are anticipated to see particularly high demand. Vitamin and mineral supplements currently dominate the market but interest in herbal supplements is growing. Major players operating in the Indian nutraceuticals space include Dabur, Dr. Reddy's, and Amway, with new companies also entering the market.
The SWOT of Social Media
This was presented to a group of county commissioners and county judges to provide them the pros and cons of social media. The goal was to show them the benefits of using it to reach customers in the county, especially by state extension agents.
Pfizer scm
Pfizer is the world's largest pharmaceutical company with revenues of $49.6 billion in 2014. It has over 78,000 employees worldwide and key products include Lipitor, Lyrica, Viagra, and Celebrex. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. Pfizer utilizes a complex global supply chain network involving over 300 suppliers to procure and deliver materials and finished products to customers in over 175 distribution centers worldwide while managing risks such as cargo theft and counterfeiting.
Dabur company SWOT analysis
Dabur India is the 4th largest FMCG company in India with over 130 years of history. It has strategic business units in healthcare, personal care, and food products with a turnover of INR 7,800 crore in 2014-15. Dabur markets its ayurvedic and herbal products in over 100 countries and is the leader in herbal digestives with 90% market share. Its product portfolio includes hair care, oral care, skin care, foods, ayurvedic health products, and pharmaceuticals. Dabur continues to innovate, expand into new categories and markets, and faces competition from other FMCG and medical companies.
Viewers also liked (16)
Dr. Liam Tully, Director, Pfizer Global Development Process Centre
Dr. Liam Tully, Director, Pfizer Global Development Process Centre
Fill Finish Contract Manufacturer Quality Benchmarking (2016)
Fill Finish Contract Manufacturer Quality Benchmarking (2016)
Similar to Pfizer: Who We Are
Marketing management project.pptx
This marketing project discusses Pfizer Inc. and analyzes the company using the 7Ps marketing mix framework. It summarizes Pfizer's diverse product portfolio and global operations. It also outlines several micro and macro factors that influence Pfizer, including regulatory environment, research and development activities, economic conditions, health trends, and technological advances.
Truth Biomedical
Shouvik Chandra founded Truth Biomedical to develop affordable healthcare solutions through biomedical engineering innovation and research. The company aims to become a leading global manufacturer of medical equipment and biomedical solutions like bionics. It plans to secure funding, set up manufacturing facilities, and expand globally to achieve sales targets over the next 3 years. Truth Biomedical performs SWOT and competition analyses and believes its focus on quality, cost effectiveness, and customer service provides advantages over other medical device companies.
Business model canvas-Hetero Healthcare Ltd(Pharmaceutical Company)
Hetero Healthcare is an Indian pharmaceutical company founded in 1993 with a vision of developing cost-effective, high quality medicines through R&D and manufacturing. Its key resources include intellectual property, scientists, and facilities worldwide. Key activities involve R&D partnerships, product development, and commercialization. Hetero partners with medical institutions and companies globally. Its value proposition is a leading position in India delivering innovative, affordable treatments to patients in over 100 countries.
Zoetis-Corporate-Brochure-web_0
Zoetis is a global leader in animal health that focuses solely on developing and providing veterinary medicines, vaccines, diagnostics and other services. They work to meet the growing global demand for animal protein and companionship. Zoetis strives to make their products and services the most valued by veterinarians and livestock producers worldwide through innovation, strong customer relationships, and reliable global supply chains.
Global health innovation guidebook
The document provides an overview of the global health innovation process from idea to implementation. It discusses 6 key challenge areas for innovators: identifying needs, understanding markets, developing products, sales/distribution, defining business models, and securing funding. The document also profiles various organizations that have developed global health solutions and discusses limitations of the research.
Kybora EM_ABI 2016
The document discusses trends in life science investing globally. It notes that while US and European healthcare IPO issuance and market volatility has fluctuated between 2010-2016, overall investment in healthcare IPOs and M&A transactions has generally increased. The document then outlines trends showing increased investment in biotech and life sciences globally, including rising investments in China and more venture capital going to biopharma companies in their Series A rounds. It concludes that given increasing medical spending, longer life expectancies and rapid innovation, it is a good time to start new life sciences businesses.
Nine Tz Overview
Nine-TZ is a healthcare business consultancy that partners with clients in North America, Europe, and Australia to help achieve their commercial objectives through business development advice, implementation, and support. They specialize in developing and executing market expansion initiatives, sourcing acquisitions, and augmenting resources. Nine-TZ leverages the expertise of its principals and advisors in areas like investment banking, marketing, and regulatory affairs to deliver a range of advisory services to pharmaceutical, biotech, and medical device companies.
Parkville strategic project final-converted
Parkville Pharmaceuticals is an Egyptian pharmaceutical company established in 2006 with headquarters in Alexandria and Cairo. It has grown from a small local company to a multinational company with over 175 employees and a diverse product range including pharmaceuticals, cosmeceuticals, dietary supplements, and medical devices. Parkville's vision is to be a key player in healthcare in the Middle East and Africa by 2025 and expand globally thereafter. Its mission is to have a strong presence in the Egyptian market and gain momentum in other fast-growing markets through innovative, high-quality, affordable products. A PESTEL analysis identifies opportunities and threats in the company's external environment.
Science Backed Success - Perspectives on the Future Growth of Natural Medicines
One aspect of complementary medicine that has changed dramatically in the last 10 years is the focus on validation of products and their claims. This has been driven on all fronts – by regulatory bodies, health professionals, consumers, and by complementary medicine companies seeking to gain a competitive edge.
Differentiation strategies for the generic industrry
This document outlines a workshop on differentiation strategies for generic drug companies. The workshop covers current differentiation approaches, challenges to differentiation, ideas for potential strategies, and future trends. Session 1 introduces the topic and reviews examples like PiSA Farmaceutica's integrated healthcare approach. Session 2 discusses challenges around resources, expertise, and changing organizations. Session 3 generates ideas around product leadership, operational excellence, and customer intimacy. Session 4 speculates on future industry shifts like prevention-focused care and personalized medicine.
ADEEVA LIFE CARE PROFILE
Adeeva Life Care Pvt. Ltd. is setup by KPS Clinical Services Pvt. Ltd. (a leading Contract Research Organization) in the auspicious of RAHE Group of Organizations.
Adeeva Life Care is a different kind of pharmaceutical and healthcare products company. We are an India based company focused on management of various kinds of ailments by developing our unique range of innovative products.
A better way to feed the planet
A corporate brochure I imagined, wrote, designed and published for Prevtec Microbia in 2013. The title became the company moto for several years.
Medical affairs department for small organization
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
Biotechnology 1
The document provides an overview of the pharmaceutical and biotechnology industries. It discusses how pharmaceutical companies produce drugs and other products, and how biotechnology companies use genetic research to develop products. It outlines trends in industry consolidation and partnerships between large pharmaceutical companies and smaller biotech firms. It also describes various career opportunities and paths within these industries.
Bhavna final
The document is a term paper analyzing the technical performance of Dr. Reddy's Laboratories, an emerging global pharmaceutical company with businesses in pharmaceutical services, generics, and proprietary products. It provides an overview of Dr. Reddy's capabilities, infrastructure, manufacturing expertise, partnerships, and board of directors. The paper also analyzes the company's financial performance from August 1-15, 2008 based on its daily stock prices.
Corporate Overview
PRA Health Sciences provides innovative drug development solutions across all phases of clinical trials and therapeutic areas. It has over 10,000 employees operating in more than 80 countries and has worked on over 3,500 clinical studies and consulting projects in the past 5 years. PRA's culture encourages employees to find creative solutions to challenges in order to help clients develop life-saving drugs. PRA has experience conducting the pivotal trials that led to approval of over 50 drugs across several therapeutic areas.
Corporate Overview_PRA
PRA Health Sciences provides innovative drug development solutions across all phases of clinical trials and therapeutic areas. It has over 10,000 employees operating in more than 80 countries and has worked on over 3,500 clinical studies and consulting projects in the past 5 years. PRA's culture encourages employees to find creative solutions to challenges in order to help clients develop life-saving drugs. PRA has experience conducting the pivotal trials that led to approval of over 50 drugs across several therapeutic areas.
johnson n johnson
Johnson & Johnson is a global healthcare company founded in 1886 in New Jersey. It has over 114,000 employees worldwide and sells its products in 175 countries. The company's segments include consumer health, pharmaceuticals, and medical devices. It has a strong presence in India dating back to 1947. Johnson & Johnson is guided by its credo which outlines priorities for customers, employees, communities, and shareholders. The company's strategic capabilities include its diverse product portfolio and global presence.
Summer Internship Report
Here are some key facts and figures about the global pharmaceutical industry:
- The global pharmaceutical market was estimated to be worth around $1.2 trillion in 2020. It is projected to reach $1.6 trillion by 2026.
- The top 10 global pharmaceutical companies by revenue in 2020 were Johnson & Johnson, Pfizer, Roche, Sanofi, Novartis, Merck & Co., AbbVie, GSK, Amgen, and Gilead Sciences.
- The top three pharmaceutical markets by sales in 2020 were the US at $360 billion, China at $145 billion, and Japan at $102 billion.
- The US accounted for around 40% of global pharmaceutical spending in 2020, despite
Scientific studies
Whether the interest is developing a new product claim, or there's the need to understand the potential effect of products use and consumption in targeted customers, res4Q is the right choice to ease the pathway and get sound data.
res4Q can identify the right methods and lead your steps towards the right direction, assisting and implementing an ad-hoc research, in order to quickly and professionally answer your necessities.
Similar to Pfizer: Who We Are (20)
Business model canvas-Hetero Healthcare Ltd(Pharmaceutical Company)
Business model canvas-Hetero Healthcare Ltd(Pharmaceutical Company)
Science Backed Success - Perspectives on the Future Growth of Natural Medicines
Science Backed Success - Perspectives on the Future Growth of Natural Medicines
Differentiation strategies for the generic industrry
Differentiation strategies for the generic industrry
Pfizer: Who We Are
- 1. Pfizer
- 3. Company Snapshot A Medicine Portfolio That Helps Prevent Disease and Promote Better Health at Every Stage of Life $71.3 Billion Combined Revenue in 2008 Sales in ~150 Countries Over 100,000 Colleagues Worldwide #1 Primary and #1 Specialty Care Company Globally Over 60 Products With Sales Greater Than $100 Million 16 Products With Sales Greater Than $1 Billion 78 Manufacturing Sites Worldwide Major R&D Operations and Partnerships in North America, Europe and Asia
- 4. Our Operating Model BioPharmaceutical Businesses Diversified Businesses Manufacturing Enabling Functions Customer Focused Primary Care Specialty Care Oncology Established Products Emerging Markets Animal Health Capsugel Consumer Healthcare Nutrition Nine Diverse Businesses Supported by Two Focused Research Organizations Business Units Including: Development, Medical, Sales & Marketing PharmaTherapeutics Research & Development BioTherapeutics Research & Development
- 5. Innovative Therapies in Key Areas of Unmet Medical Needs Neuroscience Oncology Pain/Inflammation Metabolic Disorders Vaccines Infectious Diseases Biotherapeutics Our Focus is on High Priority Disease Areas and Enhanced Biologics Capabilities
- 6. Research & Development – Highlights The Long Road to a New Medicine * 12-15 Year Process Discovery Exploratory Development Registration Full Development Idea Candidate Medicine Tested in 3-10,000 Patients (Phase III) Studies in 100-300 Patients (Phase II) Clinical Data Analysis New Medicine Formulations Developed Large Amounts of Candidate Medicine Synthesized Extensive Safety Studies Studies in Healthy Volunteers Phase I Project Team and Plans Early Safety Studies Candidate Screening Synthesis of Compounds
- 7. Research & Development – Highlights Our Pipeline (as of October 16, 2009) Pfizer Discovery Portfolio includes projects from BBC, IDU and PGRD as at Sept 2, 2009 Pfizer Clinical Portfolio (Phase 1 and beyond) includes publicly disclosed projects as of Sept 2, 2009 Wyeth Portfolio as of July 21, 2009 Pfizer Wyeth Phase 1 Phase 2 Phase 3 Reg Discovery Projects 42 31 25 3 199 14 16 7 4 240 259 360 Combined Portfolio Total = 600
- 8. What does all of this mean for you?
- 11. customer focus community respect for people performance collaboration leadership integrity quality innovation
Editor's Notes
- Source: IR Presentation – 01.26.09